Four-year complete remission with reduced-dose PARP inhibitor in advanced-stage epithelial ovarian cancer harboring a BRCA1 mutation: a case report of a chemotherapy-intolerant patient with idiopathic thrombocytopenic purpura
This case underscores the potential role of PARP inhibitors as a safe and effective alternative for ovarian cancer patients with concurrent ITP, maintaining both favorable oncologic result and hematologic stability.
Authors
- Xinmiao Bao
- Peiyao Lu
- Dan Wang (ORCID: https://orcid.org/0000-0003-1287-404X)
- Hanmei Wang (ORCID: https://orcid.org/0000-0002-0374-8300)
- Tienan Zhu
- Xirun Wan
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Shaoxing People's Hospital (CN)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1186/s13048-025-01865-2
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05